1

Supplementary data

2 **3.1.** Identification of *in vitro* phase I TND metabolites.

3 1.1. Identification of the M2 metabolite.

4 The M2 metabolite of TND was detected at (m/z 581) in the MS scan mode at a t_R of 27.3 min. 5 CID of MIPs at (m/z 581) provided various product ions (Fig. S1). The product ion at (m/z 126) 6 indicated no metabolic reaction at part A. The product ion at (m/z 402) indicated a hydroxylation 7 metabolic reaction (increase of 16 in m/z) at part B. The product ion at (m/z 563) indicated 8 dehydration (water loss) revealing hydroxylation at the piperazine moiety. The remaining 9 metabolic reaction involves a reduction proposed at part C (reduction of the carbonyl moiety of 10 the amide group) (Scheme S1).







14



18 *1.2.* Identification of the M3 and M4 metabolites.

19 The M3 and M4 metabolites of TND were detected at (m/z 577) in the MS scan mode at 20 t_R values of 37.7 and 41.3 min, respectively. The CID of MIPs at (m/z 577) provided different 21 product ions (Figs. S2A and S2B).



In the case of M3, in comparison with product ions of TND, product ions at $(m/z \ 140)$ and $(m/z \ 400)$ showed a 14 m/z increase indicating an oxidation metabolic reaction at the piperidine ring (part A) (Scheme S2).





In the case of M4, by comparing to product ions of TND, product ion at $(m/z \ 126)$ indicated no metabolic reaction at part A that matched with the other product ion at $(m/z \ 452)$ (Scheme S3). The only possible remaining metabolic site is the oxidative metabolic reaction at the piperazine ring (part A)



33

34 Scheme S3: Proposed CID of M4.

35

36 1.3. Identification of the M5 metabolite.

37 The M5 metabolite of TND was detected at (m/z 579) in the MS scan mode at a t_R of 27.2 min.

38 CID of MIPs at (*m/z* 579) provided product ions at (*m/z* 561), (*m/z* 126), (*m/z* 384), and (*m/z* 428)

39 (Fig. S3). The product ion at $(m/z \ 126)$ indicated no metabolic reaction at part A. The product ion

40 at (m/z 384) indicated water loss (decrease of 18 m/z) and a hydroxylation metabolic reaction at

41 part B. The product ion at (m/z 561) indicated water loss, revealing hydroxylation at the

42 piperazine moiety. No metabolic reaction was expected at parts A or C (Scheme S4).







45

46 Scheme S4: Proposed CID of M5.

47

48 2. Identification of TND in vivo phase I and phase II metabolites

49 2.1. Identification of the M8 metabolites of TND.

50 The M8 metabolite of TND was detected at (m/z 579) in the MS scan mode at a t_R of 27.2 min.

51 The CID of MIPs at (m/z 579) generated product ions at (m/z 386) and (m/z 126) (Fig. S4). In 52 comparison to TND product ions, the product ion at (m/z 126) indicated no metabolic reaction at 53 part A. The product ion at (m/z 386) indicates no metabolic reaction at part B. The hydroxylation 54 metabolic reaction was predicted at part C, which is most likely at the isopropyl group and 55 matches with *in silico* predictions (Scheme S5).







- 61 Scheme S5: Proposed CID of M8.
- 62
- 63 2.2. Identification of the M9 metabolites of TND.

64 The M9 metabolite of TND was detected at (m/z 591) in the MS scan mode at a t_R of 40 min. 65 CID of the MIPs at (m/z 591) generated product ions at (m/z 438), (m/z 414), and (m/z 154) (Fig. 66 S5). In comparing to TND product ions, the product ion at (m/z 438) indicated no metabolic 67 reaction at parts B or C. The product ion at (m/z 154) indicated that the metabolic reaction 68 occurred at part A, which matched with the other product ion at (m/z 414). Two α oxidation 69 metabolic reactions were predicted at the piperidine ring of part A (Scheme S6).





- 73 Scheme S6: Proposed CID of M9.